Form 4: Xeris Biopharma Director John Johnson Acquires Shares Following Milestone Achievement

Director John Johnson acquired 89,571 shares of Xeris Biopharma Holdings, Inc. common stock due to the achievement of a Keveyis sales milestone.

Summary

• On March 15, 2024, John Johnson, a director of Xeris Biopharma Holdings, Inc., acquired 89,571 shares of common stock.
• This acquisition was a result of achieving the Keveyis Sales 2023 milestone, which triggered the settlement of a Contingent Value Right (CVR) in shares of Xeris Biopharma.
• Following the transaction, Johnson directly owns 840,983 shares of Xeris Biopharma common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the acquisition of shares by a director following a milestone achievement suggests confidence in the company's performance. However, it's a routine filing and doesn't provide substantial new information.

Positives

• The achievement of the Keveyis Sales 2023 milestone indicates positive performance for the product.
• Director's increased stake in the company may signal confidence in Xeris Biopharma's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of shares, which can be interpreted as a sign of confidence in the company's performance and future.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.
• Employees may feel more secure knowing that a director is confident in the company's prospects.

Key Dates